22.66
+3.19%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Balaxi Pharmaceuticals
Its shares trade on NSE under the ticker BALAXI.NS. It has been listed since 30 November 2015. In the fiscal year to 31 March 2026, it reported revenue of ₹2.73bn and net income of ₹14.2m. At that date it held total assets of ₹3.37bn and shareholders' equity of ₹2.49bn.
Balaxi Pharmaceuticals Ltd. engages in the exportation of pharmaceutical, hardware, and FMCG products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2015-11-30. The firm is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. The company has a portfolio across multiple therapeutic segments, stock & sell models, and supplying branded and generic medicines. The firm is offerings more than 300 products across multiple therapeutic areas, including Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhoea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its consumer products include Nice 45 G, Guloso 45 G, Snax! 42 G, Doce E Sal 42 G, Yumm 75 G and Boadent.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 30 Nov 2015
- Employees
- 51
- Website
- balaxipharma.in ↗
Leadership
Pay as last reported
- Mr. Ashish MaheshwariExecutive Chairman of the Board, Managing Director, since 2017₹3.3m
- Mr. Amol MantriChief Financial Officer
- Mr. Pranav MaheshwariSenior Vice President - Business Development, since 2021
- Mr. Mohith KhandelwalCompliance Officer, Company Secretary
- Mr. Jignesh ShahFinance Controller, Angola
- Mr. Ram ChawlaCountry Head, Angola
- Mr. Bharat JawaraniSales Head, Dominican Republic
- Mr. Manish JumnaniSales Head, Guatemala
- Mr. Karan KapoorHead - Operations, Dominican Republic
- Ms. Paridhi MaheshwariHead - Alternate Channels
- Mr. Laksh ShewakramaniCompliance Head, Angola
- Mr. Pankaj SinghHead - Operations, Guatemala
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Balaxi Pharmaceuticals Ltd. exports pharmaceuticals, hardware, and FMCG products from Hyderabad, India.
- The company offers over 300 products across multiple therapeutic segments including Anti-biotic and Analgesic.
- Balaxi employs 51 full-time staff focusing on frontier markets with a growing drug portfolio.
Weaknesses
- Balaxi Pharmaceuticals Ltd. has a limited workforce of 51 employees for its extensive product range.
- The company's focus on frontier markets may restrict access to larger, more developed markets.
- Balaxi's product portfolio includes generic medicines but lacks branded pharmaceutical innovation.
Opportunities
- Balaxi can expand its export of branded medicines to emerging markets in Africa and Southeast Asia.
- The growing demand for Anti-Malaria and Anti-Tuberculosis drugs presents a significant opportunity.
- Balaxi's portfolio of 300+ products supports expansion into new therapeutic segments like Dietary Supplements.
Threats
- Balaxi faces competition from established pharmaceutical firms in the Health Care sector.
- Increasing regulatory scrutiny in frontier markets could impact export operations.
- The company's reliance on a small team of 51 employees may hinder scalability during market growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.